A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
Abstract Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic com...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-018-28987-6 |